Skip to main content
. 2018 May 10;9(5):540. doi: 10.1038/s41419-018-0597-7

Fig. 2. cZRANB1 knockdown reduces retinal reactive gliosis and facilitates RGC survival in vivo.

Fig. 2

a Eight weeks after microbead injection, the rat retinas were injected with 5 μl scramble (Scr) shRNA, cZRANB1 shRNA-1, cZRANB1 shRNA-2, cZRANB1 shRNA-3, or left untreated (Ctrl) for 7 days. qRT-PCRs were conducted to detect cZRANB1 expression (n = 5, *P < 0.05 vs. Ctrl group). b Eight weeks after microbead injection, retinal slices were stained with GFAP to detect retinal reactive gliosis in PBS buffer-, Scr shRNA-, and cZRANB1 shRNA1-injected glaucomatous retinas (n = 5, *P < 0.05 vs. buffer group). c Eight weeks after microbead injection, retinal slices were stained with TUJ1 to detect RGC survival in healthy retina (Ctrl) and PBS buffer-, Scr shRNA-, and cZRANB1 shRNA1-injected glaucomatous retinas (n = 5, *P < 0.05 vs. Ctrl group). Scale bar, 100 µm. GCL ganglion cell layer, INL inner nuclear layer, ONL outer nuclear layer. ** indicates significant difference compared with the corresponding control group